• DAPI (hydrochloride): Technical Guide for DNA Staining Workf

  2026-06-05

  DAPI (hydrochloride) is a DNA-specific fluorescent probe optimized for reliable chromosome staining, DNA visualization in histochemistry, and cell cycle analysis in both fixed and live cells. This dye is best suited for protocols requiring precise DNA quantitation and minor groove binding specificity; however, users should be aware of its limited permeability in live cells and incompatibility with ethanol-based solutions.

• HDAC Inhibitors Repress NUT Function in NUT Carcinoma Models

  2026-06-05

  Shiota et al. present a high-throughput screen identifying diverse histone deacetylase (HDAC) inhibitors as potent repressors of NUT transcriptional activity in NUT carcinoma (NC). Their findings clarify the mechanistic interplay between chromatin acetylation, megadomain regulation, and oncogenic gene expression, highlighting new therapeutic angles for this aggressive cancer.

• EdU Flow Cytometry Assay Kits (Cy5): High-Fidelity DNA Synth

  2026-06-04

  EdU Flow Cytometry Assay Kits (Cy5) enable sensitive, direct quantification of S-phase DNA synthesis via copper-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry. This platform outperforms traditional BrdU-based methods by eliminating harsh denaturation steps, improving sensitivity and preserving cell integrity.

• Applied Workflows with BCL-XL Inhibitor A-1155463 in Cancer

  2026-06-04

  A-1155463, a highly selective BCL-XL inhibitor from APExBIO, empowers researchers to dissect apoptotic pathways and overcome drug resistance in both solid tumors and hematological malignancies. This article provides actionable workflows, troubleshooting tips, and contextualizes evidence from recent landmark studies to maximize experimental success.

• Azithromycin (SKU B1398): Reliable Workflows for Infection R

  2026-06-03

  This article addresses common laboratory challenges in bacterial infection and cytotoxicity assays, focusing on the reliable use of Azithromycin (SKU B1398). Grounded in evidence and real-world scenarios, it explores protocol optimization, resistance analysis, and vendor selection for robust, reproducible results.

• AT13387: Precision Hsp90 Inhibition and Apoptosis Pathway In

  2026-06-03

  Explore AT13387, an advanced Hsp90 inhibitor, with a deep dive into its molecular action, pharmacokinetics, and unique applications in apoptosis research. This article uniquely bridges mechanistic findings from recent apoptosis studies to practical cancer biology workflows.

• MRT68921: Precision ULK1 Kinase Inhibition for Autophagy Res

  2026-06-02

  MRT68921 enables researchers to dissect autophagy signaling with nanomolar precision by selectively inhibiting ULK1/2 kinases. Its robust blockade of ATG13 phosphorylation and LC3 flux measurement sets a new standard for experimental reproducibility, especially when compared to traditional autophagy modulators.

• O-GlcNAcylation Drives Wnt-Induced Bone Formation via Glycol

  2026-06-02

  The reference study reveals that O-GlcNAcylation is indispensable for Wnt3a-driven bone formation, linking Wnt signaling to metabolic rewiring in osteoblasts. These findings clarify how Wnt signaling modulates aerobic glycolysis to promote osteogenesis, offering mechanistic insights relevant to bone disease research.

• Translating RITA (NSC 652287) Into Precision Cancer Research

  2026-06-01

  This thought-leadership article explores how RITA (NSC 652287), a potent MDM2-p53 interaction inhibitor, is redefining translational cancer research. It examines the molecule’s mechanistic underpinnings, rigorous in vitro and in vivo validation, and its strategic fit within advanced assay workflows. The narrative connects the latest advances in viability metrics to practical protocol design, highlighting APExBIO’s leadership in enabling reproducible, actionable data for renal carcinoma and broader cancer biology. Unique insights highlight how nuanced understanding of growth inhibition versus cell death, inspired by recent dissertation findings, can elevate the translational value of preclinical models.

• Targeting AR and ARv7 in TNBC: EPI-001’s Mechanistic Insight

  2026-06-01

  This study establishes the prognostic significance of androgen receptor (AR) and its splice variant ARv7 in triple-negative breast cancer (TNBC), revealing their association with metastasis and poor survival. The reference work demonstrates that N-terminal domain inhibition, particularly via EPI-001, disrupts metastatic signaling and epithelial–mesenchymal transition pathways, offering a mechanistically grounded strategy for AR-driven TNBC models.

• Nanoparticle-Enhanced Scaffolds Target Macrophages for Bone

  2026-05-31

  The reference study presents a multifunctional scaffold integrating magneto-piezoelectric nanoparticles to both disrupt bacterial biofilms and activate oxidative phosphorylation in Icam1+ macrophages, thereby promoting regeneration in infectious bone defects. These findings establish a mechanistic link between JAK2/STAT3 pathway activation and immunomodulation in bone healing, with practical implications for scaffold design in regenerative medicine.

• DiR (DiIC 18 (7)) for High-Fidelity EV Tracking and MPS Evas

  2026-05-30

  DiR (DiIC 18 (7)) unlocks unprecedented sensitivity for tracking extracellular vesicles (EVs) in vivo, enabling researchers to overcome mononuclear phagocyte system (MPS) clearance. Its near-infrared fluorescence, low cytotoxicity, and long-term membrane retention empower advanced regenerative medicine studies and innovative therapeutic workflows.

• TNF-alpha in Transcription-Independent Apoptosis: New Fronti

  2026-05-29

  This thought-leadership article explores how recombinant murine TNF-alpha is redefining the study of apoptosis, particularly in the context of emerging evidence that cell death can be triggered via active signaling pathways independent of global transcriptional shutdown. Integrating recent mechanistic insights—especially those from Harper et al. (2025)—with workflow advances, the article provides translational researchers with strategic guidance for leveraging TNF-alpha-induced signaling in experimental design. The piece highlights the unique value proposition of the APExBIO TNF-alpha recombinant murine protein, offering actionable recommendations, protocol parameters, and a visionary outlook rooted in the evolving landscape of cell death research.

• Azithromycin in Antibacterial Drug Resistance: Mechanisms an

  2026-05-29

  Discover how Azithromycin, a macrolide antibiotic, advances bacterial infection research by revealing nuanced resistance mechanisms and assay strategies. This article uniquely integrates foundational reference insights with practical workflows for high-fidelity antimicrobial research.

• Quantifying Leucomycin Impurities: HPLC-CAD and UV Method Ad

  2026-05-28

  This study introduces a validated HPLC-CAD method and its UV-based adaptation for quantitative analysis of impurities in leucomycin bulk drugs and tablets, overcoming the lack of impurity reference standards. These methods enable more reliable impurity profiling and set a precedent for future pharmacopeial guidelines, impacting the quality control of macrolide antibiotics.

442 records 15/30 page Previous Next First page 上5页 1112131415 下5页 Last page